Photo by christya_v from unsplash
RANKL is a key regulator of bone resorption that may also modulate glucose metabolism. Denosumab (DMAb) is a fully human monoclonal antibody that binds RANKL and was associated with fracture… Click to show full abstract
RANKL is a key regulator of bone resorption that may also modulate glucose metabolism. Denosumab (DMAb) is a fully human monoclonal antibody that binds RANKL and was associated with fracture risk reduction in the FREEDOM trial. We hypothesized that DMAb treatment decreased fasting serum glucose (FSG) relative to placebo in women with diabetes or prediabetes enrolled in FREEDOM trial.
Keywords:
trial;
diabetes prediabetes;
freedom trial;
effect denosumab;
women diabetes
Journal Title: Diabetes/Metabolism Research and Reviews
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes/Metabolism Research and Reviews
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!